Search

Your search keyword '"Choi, Sun-Mi"' showing total 945 results
Start Over Author "Choi, Sun-Mi"
945 results on '"Choi, Sun-Mi"'

7. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

Author

Anderson, Adam, Morgenthau, Adam, Gaser, Adrian, Vizel, Alexander, Speranskaya, Alexandra, Gerke, Alicia, Goksel, Altinisik, Undurraga, Alvaro, Sharma, Amita, Oh, Andrea, Leung, Ann, Larici, Anna Rita, Prasse, Antje, Mazzei, Antonietta, Morais, Antonio, Bhalla, Ashu, Del Rio, Belen, Jankharia, Bhavin, Elicker, Brett, Pereira, Carlos, Biegelman-Aubry, Catherine, White, Charles, Ravaglia, Claudia, Hsia, Connie, Schaefer-Prokop, Cornelia, Launay, David, Talwar, Deepak, Castillo, Diego, Patel, Divya, Israel-Biet, Dominique, Valeyre, Dominique, Britt, Edward James, Bargagli, Elena, Bendstrup, Elisabeth, Crouser, Elliott, Nossent, Esther, Shmelev, Eugeny, Porquera, Eva Carmona, Bonella, Francesco, Cohen-Aubart, Fleur, Jeny, Florence, Ferrara, Giovanni, Jin, Gong Yong, Robbie, Hasti, Prosch, Helmut, Sumikawa, Hiromitsu, Ling-Pei, Ho, Lee, Ho Yun, Strambu, Irina, Buendia-Roldan, Ivette, Grutters, Jan, Ryu, Jay, Swigris, Jeff, Miedema, Jelle, Goo, Jin Mo, Barnett, Joseph, Verschakelen, Johny, Goldin, Jonathan, Seo, Joon Beom, Enghelmayer, Juan, Mana, Juan, Behr, Juergen, Patterson, Karen, Antoniou, Katerina, Brown, Kevin, Fujimoto, Kiminori, Savale, Laurent, Maier, Lisa, Richeldi, Luca, Neto, Manuel Lessa Ribeiro, Humbert, Marc, Judson, Marc, Veltkamp, Marcel, Wilsher, Margaret, Molina, Maria, Otaola, Maria, Revel, Marie-Pierre, Silva, Mario, Drent, Marjolein, Schiebler, Mark, Wijsenbeek-Lourens, Marlies, Bonifazi, Martina, Remy-Jardin, Martine, Koslow, Matthew, Balter, Meyer, Kreuter, Michael, Thillai, Muhunthan, Hamzeh, Nabeel, Chaudhuri, Nazia, Mogulkoc, Nesrin, Todd, Nevins, Screaton, Nick, Goh, Nicole, Shah, Nirav, Obi, Ogugua, Shlobin, Oksana, Baranova, Olga, Bresser, Paul, Rottoli, Paula, Brillet, Pierre-Yves, Said-Hartley, Qonita, Borie, Raphael, Mostard, Remy, van Zyl-smit, Richard, Kairalla, Ronaldo, Egashira, Ryoko, Boussouar, Samia, Lee, Sang Min, Bhalla, Sanjeev, Tomassetti, Sara, Quadrelli, Silvia, Hart, Simon P, Danoff, Sonye, Rajan, Sujeet, Choi, Sun Mi, Copley, Susan, Kim, Tae Jung, Johkoh, Takeshi, Corte, Tamera, McLoud, Theresa, Wessendorf, Thomas, Alfaro, Tiago, Arai, Toru, Costabel, Ulrich, Vicens-Zygmunt, Vanesa, Poletti, Venerino, Cottin, Vincent, Vucinic, Violeta, Wuyts, Wim, van Es, Wouter, Jeong, Yeon Joo, Inoue, Yoshikazu, Desai, Sujal R, Sivarasan, Nishanth, Johannson, Kerri A, George, Peter M, Culver, Daniel A, Devaraj, Anand, Lynch, David A, Milne, David, Renzoni, Elisabetta, Nunes, Hilario, Sverzellati, Nicola, Spagnolo, Paolo, Baughman, Robert P, Yadav, Ruchi, Piciucchi, Sara, Walsh, Simon L F, Kouranos, Vasileios, and Wells, Athol U

Published
2024
Full Text
View/download PDF

15. Diagnostic value of serum vascular endothelial growth factor-D in Korean patients with lymphangioleiomyomatosis.

Author

Yoon, Hee-Young, Moon, Su-jin, Kim, Song Yee, Park, Jong Sun, Choi, Sun Mi, Kang, Hyung Koo, and Song, Jin Woo

Subjects
KOREANS, IDIOPATHIC pulmonary fibrosis, CHILDBEARING age, ENZYME-linked immunosorbent assay, RECEIVER operating characteristic curves, IDIOPATHIC interstitial pneumonias
Abstract

Background: Lymphangioleiomyomatosis (LAM) is a rare multisystemic disorder characterized by the proliferation of abnormal smooth muscle-like cells. Although serum vascular endothelial growth factor-D (VEGF-D) is currently used as a diagnostic biomarker for LAM, its diagnostic value in Korean patients is unclear. Objectives: To evaluate the diagnostic value of serum VEGF-D for LAM in Korean patients. Design: A multicenter prospective cohort study Methods: Serum samples were prospectively collected from five medical institutions, from patients with LAM (n = 40) and controls (n = 24; healthy participants = 3, other cystic lung diseases = 13, idiopathic pulmonary fibrosis = 4, idiopathic nonspecific interstitial pneumonia = 4). Serum VEGF-D levels were measured using the enzyme-linked immunosorbent assay, and the diagnostic value was evaluated using receiver operating characteristic (ROC) curve analysis. Results: The mean age of patients with LAM was 44.5 years, and all were female (controls: 47.8 years; female: 70.8%, p < 0.001). The serum VEGF-D levels were significantly higher in patients with LAM than those in the control group (median: 708.9 pg/mL vs 325.3 pg/mL, p < 0.001). In the ROC curve analysis, serum VEGF-D levels showed good predicting performance for LAM diagnosis (area under the curve = 0.918) with an optimal cut-off value of 432.7 pg/mL (sensitivity = 85.0%, specificity = 87.5%). When 800 pg/mL was used as the cut-off value, the specificity of serum VEGF-D for LAM diagnosis increased to 100.0%. Conclusion: Our results suggest that serum VEGF-D may be a useful biomarker for diagnosing LAM in Korean patients, similar to previous reports. Plain Language Summary: Blood test for diagnosis of lymphangioleiomyomatosis in Korea: role of vascular endothelial growth factor-D In this study, we discuss a blood test to diagnose a rare lung disease, called lymphangioleiomyomatosis (LAM). LAM primarily affects women, especially during their childbearing years, and can cause serious lung problems such as damage and cyst (air-filled sac) formation. The blood test looks for a special protein in the blood, called vascular endothelial growth factor-D (VEGF-D). If someone has a lot of this protein, it usually means that they have LAM. We have found that when VEGF-D levels are high, the test can effectively separate LAM from other lung diseases. We also found that raising this threshold to higher levels made it much more likely to correctly distinguish a group of people who do not have the disease from patients with LAM. Our study is important because it's the first to show the usefulness of blood VEGF-D testing in Korean LAM patients, and because it suggests an easier and less inconvenient way for physicians to diagnose LAM in Koreans. Our findings are an important step in improving the management of Korean patients with LAM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. A study on the status and applicability of Korean medicine EMR for establishment of Korean medicine standard EMR certification criteria: Through surveys of Korean medical institutions and Korean medicine EMR companies

Author

Heo, You Jin, primary, Lee, Cham Kyul, additional, Ryu, Soo Min, additional, Byun, Jung Won, additional, Roh, Jeong Du, additional, Jo, Na Young, additional, Seo, Byung Kwan, additional, Park, Yeon Cheol, additional, Baek, Yong Hyeon, additional, Kim, Jung Hyun, additional, Choi, Sun Mi, additional, Yoon, Young Heum, additional, and Lee, Eun Yong, additional

Published
2023
Full Text
View/download PDF

25. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

Author

Lee, Jung-Kyu, Lee, Ji Yeon, Kim, Deog Kyeom, Yoon, Ho Il, Jeong, Ina, Heo, Eun Young, Park, Young Sik, Jo, Yong Suk, Lee, Jae Ho, Park, Sung Soo, Park, Jong Sun, Kim, Junghyun, Lee, Sang-Min, Joh, Joon-Sung, Lee, Chang-Hoon, Lee, Jinwoo, Choi, Sun Mi, Park, Ju-Hee, Lee, Sang Hoon, Cho, Young-Jae, Lee, Yeon Joo, Kim, Se Joong, Kwak, Nakwon, Hwang, Yong Ran, Kim, Hyeonjeong, Ki, Jongeun, Lim, Ji Na, Choi, Hyoung Sook, Lee, Myungsun, Song, Taeksun, Kim, Hyun Su, Han, Jiyeon, Ahn, Heejung, Hahn, Seokyung, and Yim, Jae-Joon

Published
2019
Full Text
View/download PDF

26. Pulse versus non‐pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Author

Hyung, Kwonhyung, Lee, Jong Hyuk, Kim, Joong‐Yub, Choi, Sun Mi, and Park, Jimyung

Subjects
IDIOPATHIC pulmonary fibrosis, DISEASE exacerbation, SURVIVAL rate, CORTICOSTEROIDS
Abstract

Background and Objective: Corticosteroids are commonly used for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE‐IPF); however, the optimal initial dose of corticosteroids remains uncertain due to a lack of sufficient evidence. We evaluated whether the administration of a pulse dose of corticosteroids resulted in improved survival outcomes compared with conventional non‐pulse dose of corticosteroids. Methods: We retrospectively analysed 238 patients with AE‐IPF treated with corticosteroids at a tertiary referral hospital between January 2013 and December 2021. Based on whether a pulse dose of corticosteroids (methylprednisolone of ≥250 mg/day or equivalent) was administered within 7 days of hospitalization for AE‐IPF, the patients were divided into the pulse and non‐pulse regimen groups. The survival outcomes were compared between the two groups using multivariable regression and propensity score‐matched analyses. Results: Among the 238 patients, 59 patients received pulse dose of corticosteroids, whereas 179 patients received conventional non‐pulse dose of corticosteroids. After adjusting for the confounding factors related to the baseline clinical and radiographic severity, compared with the conventional non‐pulse regimen, the pulse regimen of corticosteroids did not reduce the risk of mortality at the 3‐month (aHR 0.84, 95% CI 0.45–1.38) or 12‐month (aHR 0.96, 95% CI 0.60–1.25) follow‐ups. Propensity score‐matched analysis revealed similar results. Conclusion: The survival outcomes of patients with AE‐IPF who received a pulse dose of corticosteroids did not differ from those of patients who received conventional non‐pulse dose of corticosteroids. Further prospective studies are required to establish the optimal initial dose of corticosteroids for the treatment of AE‐IPF. A pulse dose of corticosteroids did not improve survival outcome of acute exacerbation of IPF when compared with conventional non‐pulse dose of corticosteroids. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. New prognostic scoring system for mortality in idiopathic pulmonary fibrosis by modifying the gender, age, and physiology model with desaturation during the six-minute walk test

Author

Lee, Jae Ha, primary, Jang, Ji Hoon, additional, Jang, Hang-Jea, additional, Kim, Song Yee, additional, Chung, Man Pyo, additional, Yoo, Hongseok, additional, Jeong, Sung Hwan, additional, Song, Jin Woo, additional, Lee, Hong Lyeol, additional, Choi, Sun Mi, additional, Kim, Young Whan, additional, Kim, Yong Hyun, additional, Park, Sung Woo, additional, Park, Jong Sun, additional, Jegal, Yangin, additional, Lee, Jongmin, additional, Uh, Soo-Taek, additional, Kim, Tae-Hyung, additional, Kim, Yee Hyung, additional, Shin, Beomsu, additional, Lee, Hyun-kyung, additional, Yang, Sei-Hoon, additional, Lee, Hyun, additional, Kim, Sang-Heon, additional, Lee, Eun-Joo, additional, Choi, Hye Sook, additional, Kang, Hyung Koo, additional, Heo, Eun Young, additional, Lee, Won-Yeon, additional, and Park, Moo Suk, additional

Published
2023
Full Text
View/download PDF

39. COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey

Author

Yoo, Hongseok, primary, Kim, Song Yee, additional, Park, Moo Suk, additional, Jeong, Sung Hwan, additional, Park, Sung-Woo, additional, Lee, Hong Lyeol, additional, Lee, Hyun-Kyung, additional, Yang, Sei-Hoon, additional, Jegal, Yangjin, additional, Yoo, Jung-Wan, additional, Lee, Jongmin, additional, Kang, Hyung Koo, additional, Choi, Sun Mi, additional, Park, Jimyung, additional, Kim, Young Whan, additional, Song, Jin Woo, additional, Park, Joo Hun, additional, Choi, Won-Il, additional, Choi, Hye Sook, additional, Park, Chul, additional, Park, Jeong-Woong, additional, and Chung, Man Pyo, additional

Published
2023
Full Text
View/download PDF

42. Additional file 1 of Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis

Author

Choi, Myeong Geun, Choi, Sun Mi, Lee, Jae Ha, Kim, Joong-Yub, and Song, Jin Woo

Abstract

Additional file 1: Table S1. Comparison of the baseline characteristics among patients with IPF according to participating centers. Table S2. Comparison of the baseline characteristics among patients with IPF according to baseline KL-6 levels. Table S3. Comparison of the baseline characteristics between the DP and no-DP groups among patients with IPF with high baseline KL-6 levels (≥ 500 U/mL).

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results